BRPI0507074A - modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina - Google Patents

modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina

Info

Publication number
BRPI0507074A
BRPI0507074A BRPI0507074-0A BRPI0507074A BRPI0507074A BR PI0507074 A BRPI0507074 A BR PI0507074A BR PI0507074 A BRPI0507074 A BR PI0507074A BR PI0507074 A BRPI0507074 A BR PI0507074A
Authority
BR
Brazil
Prior art keywords
treatment
retinal diseases
degenerative retinal
modalities
retinal
Prior art date
Application number
BRPI0507074-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Irina V Klimanskaya
Original Assignee
Advanced Cell Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cell Tech Inc filed Critical Advanced Cell Tech Inc
Publication of BRPI0507074A publication Critical patent/BRPI0507074A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
BRPI0507074-0A 2004-01-23 2005-01-24 modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina BRPI0507074A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23
PCT/US2005/002273 WO2005070011A2 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Publications (1)

Publication Number Publication Date
BRPI0507074A true BRPI0507074A (pt) 2007-06-19

Family

ID=34807248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507074-0A BRPI0507074A (pt) 2004-01-23 2005-01-24 modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina

Country Status (15)

Country Link
US (6) US7736896B2 (cg-RX-API-DMAC7.html)
EP (8) EP2438815A3 (cg-RX-API-DMAC7.html)
JP (10) JP2007522131A (cg-RX-API-DMAC7.html)
KR (3) KR101258292B1 (cg-RX-API-DMAC7.html)
CN (3) CN1968608B (cg-RX-API-DMAC7.html)
AU (6) AU2005207042B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507074A (cg-RX-API-DMAC7.html)
CA (2) CA2555370C (cg-RX-API-DMAC7.html)
ES (1) ES2721174T3 (cg-RX-API-DMAC7.html)
HK (2) HK1216068A1 (cg-RX-API-DMAC7.html)
IL (3) IL177015B (cg-RX-API-DMAC7.html)
MX (4) MX375061B (cg-RX-API-DMAC7.html)
NZ (1) NZ548929A (cg-RX-API-DMAC7.html)
SG (4) SG10201912182UA (cg-RX-API-DMAC7.html)
WO (1) WO2005070011A2 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG10201912182UA (en) * 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
AU2007248412A1 (en) 2006-05-03 2007-11-15 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
JP5441099B2 (ja) * 2007-01-18 2014-03-12 独立行政法人理化学研究所 視細胞への分化誘導方法
EP2121902A4 (en) 2007-02-23 2010-12-22 Advanced Cell Tech Inc HIGHLY EFFICIENT METHODS OF RENEWING DIFFERENTIATED CELLS AND GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM NEWLY PROGRAMMED CELLS
JP5395058B2 (ja) * 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
CA3177952A1 (en) * 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
CA2721952C (en) * 2008-04-22 2019-11-12 Regenerative Research Foundation Retinal pigment epithelial stem cells
CA3066806C (en) 2009-08-24 2023-03-07 David M. Gamm Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
EP3549617B1 (en) 2010-07-12 2023-09-13 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
JP6189829B2 (ja) 2011-05-13 2017-08-30 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ Ｚｓｃａｎ４とｚｓｃａｎ４依存性遺伝子を利用した体細胞の直接的な再プログラム化
KR101972610B1 (ko) 2011-05-18 2019-04-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 망막 질환을 치료하기 위한 조성물 및 방법
WO2013015835A1 (en) 2011-07-22 2013-01-31 Seven Networks, Inc. Mobile application traffic optimization
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
HUE044778T2 (hu) 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
CN104136601A (zh) * 2012-02-17 2014-11-05 斯格本斯眼科研究所 人视网膜祖细胞的表型谱
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CN113088481A (zh) * 2012-08-24 2021-07-09 独立行政法人理化学研究所 用于生产视网膜色素上皮细胞片层的方法
EP4292600A3 (en) 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP2980207B1 (en) * 2013-03-25 2018-12-05 Foundation for Biomedical Research and Innovation at Kobe Cell sorting method
EP2796545A1 (en) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
ES2763433T3 (es) 2013-11-27 2020-05-28 Kyoto Prefectural Public Univ Corp Aplicación de laminina a cultivos de células endoteliales de la córnea
WO2015087231A1 (en) 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
JP6770435B2 (ja) 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
WO2016067628A1 (ja) 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる角膜の新規治療
IL303401A (en) 2015-03-23 2023-08-01 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
CN108350421A (zh) 2015-09-08 2018-07-31 大日本住友制药株式会社 用于制备视网膜色素上皮细胞的方法
CN108291206B (zh) 2015-09-08 2022-07-08 富士胶片细胞动力公司 干细胞来源的视网膜色素上皮的基于macs的纯化
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
CN108350429B (zh) 2015-10-20 2022-02-25 富士胶片细胞动力公司 用于将多能干细胞定向分化为免疫细胞的方法
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
US11618883B2 (en) 2017-03-08 2023-04-04 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
US20200085882A1 (en) * 2017-03-16 2020-03-19 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
KR102668891B1 (ko) 2017-04-18 2024-05-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 항원-특이적 면역 이펙터 세포
CN111094548A (zh) * 2017-09-14 2020-05-01 国立研究开发法人理化学研究所 基于背侧化信号转导物质或腹侧化信号转导物质的增加视锥细胞或视杆细胞的方法
CA3082080A1 (en) * 2017-11-15 2019-05-23 Friedrich Miescher Institute For Biomedical Research Primate retinal pigment epithelium cell-specific promoter
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
US11946069B2 (en) 2018-03-12 2024-04-02 RxCell, Inc. Method for generating multiple cellular products from single pluripotent cell source
CA3137528A1 (en) 2019-04-26 2020-10-29 Riken Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same
IL292610A (en) * 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
JPWO2022191216A1 (cg-RX-API-DMAC7.html) 2021-03-09 2022-09-15
TW202330906A (zh) 2021-11-19 2023-08-01 國立研究開發法人理化學研究所 片狀視網膜組織之製造方法
CA3254454A1 (en) 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
CN119384700A (zh) 2022-04-15 2025-01-28 艾斯本神经科学公司 细胞分化状态的分类方法和分化细胞的相关组合物
EP4659755A1 (en) 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196923T1 (de) 1993-04-30 2000-10-15 Photogenesis Inc Transplantation des retinalen pigmentepithels
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
EP1044024A1 (en) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
EP1066368A4 (en) 1998-03-02 2002-08-21 Compucyte Corp SELECTIVE CELL ANALYSIS
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
NZ518365A (en) 1999-10-28 2004-04-30 Univ Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
JP2003533976A (ja) 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
JP2004514702A (ja) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド 眼における移植拒絶を予防するための眼内インプラント
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
JP2004531262A (ja) 2001-05-15 2004-10-14 ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ ヒト胚性幹細胞由来インスリン産生細胞
KR101073411B1 (ko) 2001-07-12 2011-10-17 제론 코포레이션 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
CA2482903A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
AU2003279132A1 (en) 2002-10-04 2004-05-04 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
JP4348706B2 (ja) * 2002-10-08 2009-10-21 日本電気株式会社 アレイ装置および携帯端末
AU2003302020B2 (en) 2002-11-14 2008-01-31 Ethicon Endo-Surgery, Inc. Methods and devices for detecting tissue cells
CN101044404A (zh) 2003-03-03 2007-09-26 长冈实业株式会社 用于不同类型细胞检测和定量的方法和装置以及生物光盘在该检测和定量中的应用
SG10201912182UA (en) 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
EP2048227B1 (en) 2005-02-11 2015-08-19 Agency For Science, Technology And Research Methods for proliferating stem cells
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
JP5395058B2 (ja) 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA3177952A1 (en) 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
HUE044778T2 (hu) 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes

Also Published As

Publication number Publication date
US20100299765A1 (en) 2010-11-25
CN1968608B (zh) 2011-06-29
HK1216068A1 (en) 2016-10-14
CN104434979A (zh) 2015-03-25
SG10201606441SA (en) 2016-09-29
IL291162A (en) 2022-05-01
ES2721174T3 (es) 2019-07-29
JP2019217356A (ja) 2019-12-26
MX375061B (es) 2025-03-06
AU2010249263B2 (en) 2013-04-18
EP4248751A3 (en) 2023-11-01
AU2016259323A1 (en) 2016-12-01
KR101398356B1 (ko) 2014-05-23
JP2020146575A (ja) 2020-09-17
EP4269561A3 (en) 2024-01-03
EP2438814A3 (en) 2012-10-03
US7736896B2 (en) 2010-06-15
MX2020009456A (es) 2020-10-12
KR20070069087A (ko) 2007-07-02
CA2937099A1 (en) 2005-08-04
AU2013201791B2 (en) 2016-08-18
NZ548929A (en) 2010-10-29
AU2016259323B2 (en) 2019-01-31
HK1162931A1 (en) 2012-09-07
JP2012148085A (ja) 2012-08-09
IL267126A (en) 2019-08-29
WO2005070011A3 (en) 2005-10-13
US20070031386A1 (en) 2007-02-08
AU2005207042B2 (en) 2010-09-09
CA2555370A1 (en) 2005-08-04
US9040770B2 (en) 2015-05-26
AU2021200601A1 (en) 2021-03-04
EP2929782A1 (en) 2015-10-14
AU2005207042A1 (en) 2005-08-04
HK1207821A1 (en) 2016-02-12
MX375065B (es) 2025-03-06
EP4269561A2 (en) 2023-11-01
AU2019200513A1 (en) 2019-02-14
IL177015A0 (en) 2006-12-10
JP2022153630A (ja) 2022-10-12
JP2024038460A (ja) 2024-03-19
JP2018086274A (ja) 2018-06-07
IL177015B (en) 2019-06-30
IL267126B (en) 2022-04-01
CA2555370C (en) 2024-02-06
EP2438814A2 (en) 2012-04-11
CN102204930B (zh) 2014-12-03
US9649340B2 (en) 2017-05-16
KR20120051754A (ko) 2012-05-22
US20180064761A1 (en) 2018-03-08
US9730962B2 (en) 2017-08-15
SG10201912182UA (en) 2020-02-27
MX343606B (es) 2016-11-11
SG188122A1 (en) 2013-03-28
CN1968608A (zh) 2007-05-23
JP2014079650A (ja) 2014-05-08
EP1708575A4 (en) 2009-07-01
US20110117062A1 (en) 2011-05-19
EP2438816A3 (en) 2012-10-03
EP2438816A2 (en) 2012-04-11
JP2016195862A (ja) 2016-11-24
EP1708575A2 (en) 2006-10-11
EP2438815A3 (en) 2012-10-03
EP2438815A2 (en) 2012-04-11
EP2438816B1 (en) 2019-03-27
KR20130025953A (ko) 2013-03-12
US20060018886A1 (en) 2006-01-26
EP4248752A3 (en) 2024-01-03
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
JP2007522131A (ja) 2007-08-09
US7795025B2 (en) 2010-09-14
US20150328261A1 (en) 2015-11-19
EP4248752A2 (en) 2023-09-27
CN102204930A (zh) 2011-10-05
JP2015096556A (ja) 2015-05-21
SG155236A1 (en) 2009-09-30
KR101258292B1 (ko) 2013-04-25
EP4248751A2 (en) 2023-09-27
WO2005070011A2 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
BRPI0507074A (pt) modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina
WO2006080952A3 (en) Improved modalities for the treatment of degenerative diseases of the retina
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
UY31520A1 (es) Proteinas de union a antigenos
EP2279247A4 (en) STEM CELLS OF THE RETINAL PIGMENTARY EPITHELIUM
TW200732347A (en) VEGF analogs and methods of use
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2009052439A3 (en) Immunotherapy regimes dependent on apoe status
BRPI0817154B8 (pt) "método de modificar uma célula de levedura para a produção de etanol, célula de levedura modificada, uso de uma célula de levedura modificada e método para a produção de etanol"
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EA200901211A1 (ru) Антигены белка с5 и их применение
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
AU2016255474A8 (en) Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease
Singh et al. Science and art of cell-based ocular surface regeneration
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
BR112022024031A2 (pt) Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmos
WO2011009193A8 (en) Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2022198138A8 (en) Ocular delivery of therapeutic agents
WO2022235551A3 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]